SUBSCRIBE
SUBSCRIBE
News   Policy

Ranbaxy Laboratories Gains in Mumbai After U.S. Withdraws Motion

October 9, 2008 | 
1 min read
Oct. 8 (Bloomberg) -- Ranbaxy Laboratories Ltd., the Indian drugmaker being purchased by Japan's Daiichi Sankyo Co., rose the most in almost three months after the U.S. withdrew a motion seeking to force the company to turn over audit reports.
Legal Regulatory Asia
MORE ON THIS TOPIC
Handshake of man and robot. Modern technologies. Art collage.
Artificial intelligence
Amid Layoffs, Delays, FDA Turns to AI for Speedy Reviews
May 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Trendy halftone collage. A hand holds a ringing alarm clock. Time, hurry up. Vector business concepts for graphic and web design, marketing and print materials, social media. Vector illustration
Regulatory
FDA Delays Continue as Regulator Misses Review Date for GSK’s Nucala
May 9, 2025
 · 
2 min read
 · 
Tristan Manalac
illustration of the ship in the storm, gigantic waves
Special edition
Deep Dive: Biopharma In Turmoil As Peter Marks Forced Out of FDA
May 9, 2025
 · 
2 min read
 · 
Annalee Armstrong
Illustration showing businessman avoiding potholes on way to goal
Job Trends
Job Market Woes: More Funding, Stability Needed for Turnaround
May 8, 2025
 · 
5 min read
 · 
Angela Gabriel